GlassScriptPhysician profile
Shari Brown
NPI 1790003044
$538.26
in general payments reported to CMS, 2019-2025
11 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.41 · 2022: $31.81 · 2023: $16.73 · 2024: $80.91 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $230.27 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $117.99 | 2021-2025 | Jardiance, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.46 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $35.74 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $22.66 | 2025 | Farxiga |
| Dexcom, INC. | $17.40 | 2021 | |
| Abbvie INC. | $16.73 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.13 | 2025 | Jardiance |
| Exact Sciences Corporation | $14.13 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $13.51 | 2025 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.